Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/24/2025

Initiating Jardiance in Type 2 Diabetes

Primary Indications for Immediate Initiation

  • The American Diabetes Association and European Association for the Study of Diabetes recommend starting Jardiance in all patients with type 2 diabetes and established atherosclerotic cardiovascular disease, including prior myocardial infarction, ischemic stroke, unstable angina, or coronary/carotid/peripheral artery revascularization, regardless of their current HbA1c level or metformin use 2, 3
  • The American Heart Association suggests that Jardiance should be initiated in patients with type 2 diabetes and chronic kidney disease (eGFR ≥20 mL/min/1.73 m²) or albuminuria (ACR ≥30 mg/g), as it reduces the risk of cardiovascular events and kidney disease progression 1, 2
  • The European Society of Cardiology recommends starting Jardiance in patients with type 2 diabetes and heart failure, particularly those with reduced ejection fraction (<45%), as it reduces the risk of heart failure hospitalization 2, 3

Secondary Indications Based on Risk Profile

  • The American College of Cardiology suggests considering Jardiance in patients aged ≥55 years with indicators of high cardiovascular risk, including coronary, carotid, or lower extremity artery stenosis >50%, left ventricular hypertrophy, eGFR <60 mL/min/1.73 m², or albuminuria (even if <300 mg/g) 2, 1

Critical Implementation Details

  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend initiating Jardiance at a dose of 10 mg once daily, with consideration for increasing to 25 mg if additional glucose lowering is needed and the medication is well tolerated 5
  • The American Diabetes Association recommends not waiting to optimize metformin or achieve specific HbA1c targets before starting Jardiance in high-risk patients, as the mortality benefit is independent of glucose lowering 4, 2

Important Safety Considerations and Monitoring

  • The European Association for the Study of Diabetes suggests avoiding Jardiance in patients with active foot ulcers or high amputation risk until careful shared decision-making occurs with comprehensive foot care education 2
  • The American Heart Association recommends monitoring for volume depletion, particularly in patients on other diuretics or antihypertensive medications, as empagliflozin has diuretic effects 6